Literature DB >> 15194633

Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?

Y Taché1.   

Abstract

New corticotropin releasing factor (CRF) antagonists in irritable bowel disease (IBS) warrant testing, and CRF1 receptors may be a promising target for the treatment of IBS.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15194633      PMCID： PMC1774121          DOI： 10.1136/gut.2003.036400

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  44 in total

Review 1.  Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors.

Authors:  Y Taché; V Martinez; M Million; L Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-02       Impact factor: 4.052

2.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 3.  Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity.

Authors:  H Mönnikes; J J Tebbe; M Hildebrandt; P Arck; E Osmanoglou; M Rose; B Klapp; B Wiedenmann; I Heymann-Mönnikes
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

4.  Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa.

Authors:  Y Muramatsu; K Fukushima; K Iino; K Totsune; K Takahashi; T Suzuki; G Hirasawa; J Takeyama; M Ito; M Nose; A Tashiro; M Hongo; Y Oki; H Nagura; H Sasano
Journal:  Peptides       Date:  2000-12       Impact factor: 3.750

5.  Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats.

Authors:  C Maillot; M Million; J Y Wei; A Gauthier; Y Taché
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

6.  Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C.

Authors:  M Malaguarnera; A Laurino; I Di Fazio; G Pistone; M Castorina; N Guccione; L Rampello
Journal:  J Interferon Cytokine Res       Date:  2001-05       Impact factor: 2.607

Review 7.  Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders.

Authors:  M E Keck; F Holsboer
Journal:  Peptides       Date:  2001-05       Impact factor: 3.750

8.  Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.

Authors:  M Yamano; H Yuki; S Yasuda; K Miyata
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

9.  Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

Authors:  A W Zobel; T Nickel; H E Künzel; N Ackl; A Sonntag; M Ising; F Holsboer
Journal:  J Psychiatr Res       Date:  2000 May-Jun       Impact factor: 4.791

Review 10.  Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.

Authors:  J Kehne; S De Lombaert
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-10
View more
  14 in total

Review 1.  The psyche and the gut.

Authors:  Paul Enck; Ute Martens; Sibylle Klosterhalfen
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

Review 2.  Psychobiotics: The Next-Generation Probiotics for the Brain.

Authors:  Richa Sharma; Deesha Gupta; Rekha Mehrotra; Payal Mago
Journal:  Curr Microbiol       Date:  2021-01-04       Impact factor: 2.188

Review 3.  Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract.

Authors:  Yvette Tache; Muriel Larauche; Pu-Qing Yuan; Mulugeta Million
Journal:  Curr Mol Pharmacol       Date:  2018       Impact factor: 3.339

4.  Can modulating corticotropin releasing hormone receptors alter visceral sensitivity?

Authors:  S Fukudo; K Saito; Y Sagami; M Kanazawa
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

Review 5.  Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Authors:  John H Kehne; Christopher K Cain
Journal:  Pharmacol Ther       Date:  2010-09-06       Impact factor: 12.310

6.  CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats.

Authors:  M Million; L Wang; Y Wang; D W Adelson; P-Q Yuan; C Maillot; S V Coutinho; J A Mcroberts; A Bayati; H Mattsson; V Wu; J-Y Wei; J Rivier; W Vale; E A Mayer; Y Taché
Journal:  Gut       Date:  2005-06-28       Impact factor: 23.059

Review 7.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

Review 8.  From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.

Authors:  Yvette Taché; Stefan Brunnhuber
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance.

Authors:  Jean E Rivier; Catherine L Rivier
Journal:  Front Neuroendocrinol       Date:  2013-11-20       Impact factor: 8.606

10.  Allosteric modulators of class B G-protein-coupled receptors.

Authors:  Sam R J Hoare
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.